A preclinical study shows that CDK 4/6 inhibitors increase the sensitivity of PIK3CA-mutant breast cancer cells to PI3K inhibitors, and the combination of the two drugs has a synergistic effect on the treatment of breast cancer [118]. The gene discussed is PIK3CD; the disease is breast carcinoma.